Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...
GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...
In late November, ResMed issued a safety notice warning that some of the masks used with its CPAP machines contain magnets that could potentially interfere with pacemakers, neurostimulators and other ...
(Reuters) - Medical equipment maker ResMed reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices. The company's quarterly revenue ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to ...
Alphabet subsidiary Verily is teaming up with well-known sleep company ResMed to form a new venture that will focus on developing sleep apnea treatments and connected health products. The latest ...
Jan 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep ...
ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback